VKH
IMUC

Virtu KCG Holdings’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Virtu KCG Holdings’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$12K Buy
+14,163
New +$23.2K ﹤0.01% 2770
2016
Q4 		– Sell
-1,308
Closed -$6K – 4190
2016
Q3 		$6K Buy
1,308
+161
+14% +$1.04K ﹤0.01% 3002
2016
Q2 		$11K Buy
1,147
+252
+28% +$2.59K ﹤0.01% 2846
2016
Q1 		$10K Sell
895
-459
-34% -$5.16K ﹤0.01% 2661
2015
Q4 		$19K Buy
1,354
+491
+57% +$8.12K ﹤0.01% 3319
2015
Q3 		$14K Sell
863
-648
-43% -$11.8K ﹤0.01% 3205
2015
Q2 		$29K Buy
+1,511
New +$29.1K ﹤0.01% 3152
2015
Q1 		– Sell
-3,388
Closed -$99K – 4526
2014
Q4 		$99K Buy
3,388
+2,720
+407% +$78.3K ﹤0.01% 3228
2014
Q3 		$24K Sell
668
-1,521
-69% -$58.6K ﹤0.01% 3457
2014
Q2 		$98K Sell
2,189
-253
-10% -$12.2K ﹤0.01% 3299
2014
Q1 		$119K Sell
2,442
-1,093
-31% -$53.5K ﹤0.01% 3163
2013
Q4 		$131K Buy
3,535
+2,878
+438% +$273K ﹤0.01% 3348
2013
Q3 		$68K Buy
+657
New +$72.1K ﹤0.01% 3460

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Virtu KCG Holdings's IMUC Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2017: 14,163 shares worth $12K. The stake represents ﹤0.01% of the portfolio and ranks #2770 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in IMUC as recently as Q3 2016.

Virtu KCG Holdings first reported a position in IMUC in Q3 2013 and has held it in 13 quarters since. The position peaked at $131K in Q4 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q2 2017.

  • Virtu KCG Holdings held 14,163 shares of ImmunoCellular Therapeutics, Ltd. worth $12K as of Q2 2017.
  • ImmunoCellular Therapeutics, Ltd. was a new Virtu KCG Holdings position in Q2 2017.
  • ImmunoCellular Therapeutics, Ltd. made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2770 holding.
  • Virtu KCG Holdings first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2013 and has held it in 13 quarters since.
  • Virtu KCG Holdings's ImmunoCellular Therapeutics, Ltd. position peaked at $131K in Q4 2013.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.